June 16th, 2014
This week’s topics include statins and physical activity in older men, transitional care interventions to prevent heart-failure readmissions, and more.
May 14th, 2014
Darren McGuire gives us his perspective on the DIGAMI trial results.
February 11th, 2013
The FDA informed Novo Nordisk on Friday that it would not approve the company’s highly anticipated long-acting insulin degludec products (Tresiba and Ryzodeg) until it receives data from a cardiovascular outcomes trial. Approval of the drugs had been widely anticipated for this year, following a positive recommendation from an FDA advisory committee last fall. But the committee […]
June 11th, 2012
A large new study has found no evidence of cardiovascular (CV) benefits for either basal insulin or omega-3 fatty acids in a population of people with diabetes or at risk for diabetes. Results of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) study were presented today at the annual meeting of the American Diabetes Association […]
May 14th, 2012
This week Richard discusses studies of glucose, insulin, and potassium for MI, elective PCI with and without surgical standby, and varenicline and CV risk.